Search Results
Your search for multiple myeloma matches 1517 pages
Showing 651 - 700Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim...
Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone
Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell...
Indiana University Researcher Receives $1.6 Million NCI Grant for Multiple Myeloma
G. David Roodman, MD, PhD, of Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center, has been awarded a 5-year, $1.6 million grant from the National Cancer Institute (NCI) to study ways to build bone and decrease tumor growth in multiple myeloma bone disease. Dr. Roodman is...
How the COVID-19 Pandemic Is Propelling the Delivery of Home Care for Patients With Cancer
In 2019, the Penn Center for Cancer Care Innovation at the University of Pennsylvania’s Abramson Cancer Center began planning a demonstration program, called Cancer Care at Home, to broaden the delivery of oncology treatments to patients in the home setting. The existing services offered by Penn...
I Have Multiple Myeloma and Am Concerned About the Coronavirus
In hindsight, the symptoms I began experiencing in the fall of 2013—sudden excruciating back bone pain and severe fatigue—should have tipped me off that I had a serious disease, but 7 years ago, they were easy to explain away. The bone pain was similar to what I had experienced several years...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, Myeloma, and Myelodysplastic Syndromes
The 2019 American Society of Hematology (ASH) Annual Meeting & Exposition featured a cornucopia of sessions. It was impossible to attend all the lectures, symposia, oral presentations, poster presentations, and special events because many were concurrent. Below, we have selected some...
Saad Z. Usmani, MD: In My Experience Question 5
For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 24, 2020.
Outcomes With Autologous-Allogeneic vs Tandem Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
In a pooled analysis reported in the journal Bone Marrow Transplantation, Costa et al found that autologous followed by reduced-intensity conditioning allogeneic hematopoietic cell transplantation (auto-allo) was associated with longer overall survival compared with tandem autologous...
Saad Z. Usmani, MD: In My Experience Question 4
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 3
Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 2
During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 1
As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible? Recorded April 24, 2020.
FDA Approves Daratumumab and Hyaluronidase-fihj in Multiple Myeloma
On May 1, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adult patients with newly diagnosed, relapsed, or refractory multiple myeloma. This new product allows for subcutaneous dosing of daratumumab. Daratumumab and hyaluronidase-fihj...
Managing Multiple Myeloma During the COVID-19 Pandemic
In dealing with coronavirus disease 2019 (COVID-19), some oncologists are modifying conventional treatment regimens to limit patients’ visits to infusion centers and providers’ offices. The ASCO Post asked C. Ola Landgren, MD, PhD, Chief of the Myeloma Service at Memorial Sloan Kettering Cancer...
Long-Term Outcomes With Triplet Induction and Risk-Adapted Maintenance Therapy for Newly Diagnosed Multiple Myeloma
As reported by Joseph et al in the Journal of Clinical Oncology, follow-up in a large cohort of patients with newly diagnosed multiple myeloma indicates good long-term outcomes with consecutive treatment with lenalidomide/bortezomib/dexamethasone (RVD) induction therapy and risk-adapted maintenance ...
Isatuximab-irfc for Previously Treated Multiple Myeloma
On March 2, 2020, the CD-38-directed cytolytic antibody isatuximab-irfc (Sarclisa) was approved for use in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.1,2...
Actively Recruiting Clinical Trials Studying Multiple Myeloma
This Clinical Trials Resource Guide lists six actively recruiting clinical trials that focus on treating multiple myeloma. These studies, ranging from phase I to phase III, are evaluating the safety and efficacy of vaccines, cytotoxic T lymphocytes, and drug treatment regimens. Some studies center ...
Addition of Isatuximab to Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
As reported in The Lancet by Michel Attal, MD, of the Institut Universitaire du Cancer Toulouse Oncopole, France, and colleagues, the phase III ICARIA-MM trial has shown that the addition of the CD38-targeted antibody isatuximab to pomalidomide and low-dose dexamethasone significantly improved...
How CRISPR-Cas9 Gene Editing May Improve the Effectiveness of Cellular Therapeutics in Patients With Cancer
The results from the first in-human phase I clinical trial in the United States evaluating CRISPR-Cas9–edited T cells in patients with advanced cancer has shown that the therapy is both feasible and safe, representing a big step forward in the potential of using gene editing to boost the natural...
It’s T Time for Peripheral T-Cell Lymphoma, a Much-Neglected Disease
The lymphomas are an incredibly complex assemblage of neoplastic diseases. They are not one disease, and, at least based on the World Health Organization (WHO) Classification of Tumors published in 2017, they represent a collection of approximately 80 different malignancies, a number that will...
After Training Across Three Continents, a Hematologist Leads the Wisconsin Hematology/Oncology Division
In this edition of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with hematologist Parameswaran Hari, MD, MRCP, Chief of the Division of Hematology and Oncology at the Medical College of Wisconsin, Milwaukee. In addition, Dr. Hari holds the Armand J. Quick/William F. Stapp Chair...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...
Case Study: Patient With Multiple Myeloma Treated for COVID-19 With Tocilizumab
A case study of one patient with multiple myeloma diagnosed with COVID-19 in Wuhan, China, published by Zhang et al in Blood Advances examined the efficacy of the immunosuppressant tocilizumab as a treatment for this particular patient. The report also suggested that patients with hematologic...
Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing
Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...
Methylation Signatures From Sequencing Circulating Cell-Free DNA Detected Different Types of Cancer Across Multiple Stages
Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated—often before there are any clinical signs or symptoms of the disease. These findings were published by Liu et al in Annals of Oncology. In their ...
Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver...
Bispecific Antibodies: Successes and Challenges
Bispecific T-cell engager (BiTE) antibodies, such blinatumomab, may be the most appealing type of bispecific antibodies, a class of manufactured constructs that is expected to expand into the solid tumor space, according to Hermann Einsele, MD, Professor of Medicine at the University of Würzburg,...
Memorial Sloan Kettering Announces Two New Appointments
Memorial Sloan Kettering Cancer Center (MSK) recently appointed Sergio Giralt, MD, and Miguel-Angel Perales, MD, as Deputy Division Head of the Division of Hematologic Malignancies and Chief of the Adult Bone Marrow Transplant Service, respectively. Dr. Giralt: New Roles and Old Former Chief of...
A Discussion About CAR T-Cell Therapy for Multiple Myeloma and Lymphoma
Dr. Armitage discusses the role of CAR T-cell therapy in the management of multiple myeloma and lymphoma in a conversation with his colleagues Dr. Holstein and Dr. Lunning.
A Case of Relapsed/Refractory Multiple Myeloma
Dr. Armitage presents a case and asks Dr. Holstein to comment about her approach to treatment. The patient is be a 59-year-old man who had presented with symptomatic myeloma with bone pain and he was feeling unwell. He had bone lesions on images. He was anemic. This all happened 2 years ago. He was ...
A Case of Smoldering Myeloma
In this episode, Dr. Armitage presents a case and asks Dr. Holstein to comment on her approach to treatment of this individual. The patient is a 65-year-old man who was referred because of a monoclonal protein found in his blood. The patient was asymptomatic. He had a normal exam. He had an IgG...
Continuous Coverage of COVID-19
The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com. Direct From ASCO:...
HAPLO2019: Advances in Haploidentical Transplantation and Other Novel Cellular Therapies
Now in its seventh year, the Haploidentical Transplant Symposium (HAPLO) continues to explore advances in haploidentical and other novel cellular therapies. The most recent of these meetings—HAPLO2019—met in Orlando, Florida, 2 days before the start of the 2019 American Society of Hematology (ASH)...
News From the 2020 Multidisciplinary Head and Neck Cancers Symposium
This week, we’ll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We’ll also review the FDA’s approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.
FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma
On March 2, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa) in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. ...
Stock Your Practice for Cancer Awareness Month in March With ASCO Answers Materials
ASCO Answers patient education materials have everything you need to stock your practice for cancer awareness month in March. From comprehensive guides to single-page fact sheets, ASCO Answers is your go-to resource for trusted oncologist-approved patient education. Check out the following popular...
Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myeloma. The initiative is being established with a $16.5 million gift from Paula and Rodger...
Redefining What It Means to Have Precursor Myeloma
Studies have shown that all patients diagnosed with multiple myeloma had a preceding asymptomatic expansion of clonal plasma cells, clinically recognized as monoclonal gammopathy of undetermined significance or smoldering multiple myeloma. According to C. Ola Landgren, MD, PhD, Professor of...
Expert Point of View: Suzanne Lentzsch, MD, PhD
Suzanne Lentzsch, MD, PhD, Professor of Medicine and Director of the Multiple Myeloma and Amyloidosis Service at Columbia University, offered her thoughts on venetoclax-based regimens, such as the one described by Dr. Kaufman. “Despite tremendous progress in the treatment of multiple myeloma, the...
Venetoclax Plus Dexamethasone Shows Activity in t(11;14) Multiple Myeloma
In a phase I/II study of patients with advanced multiple myeloma and t(11;14) translocations, the combination of venetoclax and dexamethasone showed strong, durable activity, even in patients refractory to daratumumab, study investigators reported at the 2019 American Society of Hematology (ASH)...
Stand Up To Cancer Announces Gastric Cancer Interception Research Team
Stand Up To Cancer (SU2C) recently announced that an international team of experts will take a new approach to fighting gastric cancer. The SU2C Gastric Cancer Interception Research Team: Early Detection and Interception of Diffuse and Intestinal Gastric Cancer was introduced at the SU2C Scientific ...
Pembrolizumab for BCG-Unresponsive, High-Risk Non–Muscle Invasive Bladder Cancer
On January 8, 2020, pembrolizumab was approved for treatment of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.1,2...
NCI’s James N. Kochenderfer, MD, Receives Clinical Research Achievement Award
James N. Kochenderfer, MD, Investigator in the Surgery Branch of the National Cancer Institute has been named a Top Ten Clinical Research Achievement Awardee by the Clinical Research Forum. Dr. Kochenderfer received the award for his research into the development of chimeric antigen receptor (CAR) ...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, and Multiple Myeloma
The ASH 2019 Annual Meeting & Exposition featured countless important sessions and lectures. It would be impossible to attend all the symposia, oral presentations, poster presentations, and special events. Below, we have selected some presentation highlights to supplement our coverage of the...
Expert Point of View: Thierry Facon, MD, and Michael Jain, MD, PhD
Thierry Facon, MD, of Lille University Hospital in France, and Michael Jain, MD, PhD, of Moffitt Cancer Center, Tampa, were interviewed by The ASCO Post on the second-generation chimeric antigen receptor (CAR) T-cell products for treating multiple myeloma. According to Dr. Facon, essentially...
Next-Generation BCMA-Targeted CAR T-Cell Therapies for Relapsed or Refractory Multiple Myeloma Explored in Early-Phase Trials
Two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses for patients with relapsed or refractory multiple myeloma, as well as potentially less cytokine-release syndrome and neurotoxicity compared with first-generation CAR T-cell products,...
Early Data Suggest Efficacy of Innovative CAR NK-Cell Therapy for B-Cell Malignancies
FT596, a novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product, was as effective as existing CAR T-cell platforms in killing cancer cells in vivo, and the combination of FT596 plus rituximab killed lymphoma cancer cells that were no longer responding to CAR T-cell...
Conference Highlights From the 2019 American Society of Hematology Annual Meeting & Exposition
More than 25,000 specialists in hematology from over 115 countries attended the 61st American Society of Hematology (ASH) Annual Meeting & Exposition held last December in Orlando. The conference featured a stunning array of 4,900 abstracts with impressive new data in the treatment of multiple...
Activity of Anti-BCMA BiTE Molecule AMG 420 in Relapsed or Refractory Multiple Myeloma
In a phase I study reported in the Journal of Clinical Oncology, Max S. Topp, MD, and colleagues found the maximum tolerated dose of the investigational anti–B cell maturation antigen (BCMA) bispecific T-cell engager (BiTE) molecule AMG 420 elicited a high response rate in patients with relapsed or ...
FDA Pipeline: Priority Reviews in Multiple Myeloma, Prostate Cancer
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for multiple myeloma and prostate cancer; gave Fast Track designation to a targeted gene therapy for lung cancer; granted Orphan Drug designation to a combination therapy for hepatocellular...
